Drug Profile
Mixed amfetamine salts - Takeda
Alternative Names: Amphetamine salts (mixed, long acting) - Takeda; d,l-Amphetamine and d-amphetamine salts (long acting) - Takeda; d,l-Amphetamine and dextroamphetamine salts (long acting) - Takeda; d-Amphetamine and d,l-amphetamine salts (long acting) - Takeda; Dextroamphetamine and d,l-amphetamine salts (long acting) - Takeda; Mydayis; SHP-465; SLI 381; SPD 465; Triple-bead mixed amphetamine salts - Takeda; Triple-bead-mixed-amfetamine-salts; Triple-bead-mixed-amphetamine-saltsLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Shire
- Developer Shire; Takeda
- Class Amphetamines; Behavioural disorder therapies
- Mechanism of Action Adrenergic receptor agonists; Central nervous system stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Attention-deficit hyperactivity disorder
Most Recent Events
- 31 Dec 2020 Supernus Pharmaceuticals in-licenses mixed amfetamine salt (MydayisTM) from Takeda, prior to December 2020
- 13 Mar 2019 Discontinued - Preregistration for Attention-deficit hyperactivity disorder ( In children) in USA (PO)
- 13 Mar 2019 Preregistration for Attention-deficit hyperactivity disorder (In children) in USA (PO)